Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 11/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 8/20 | 0.56 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.56 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | MMP2 | P08253 | 3/20 | 0.45 |
| ▸ | MMP9 | P14780 | 3/20 | 0.45 |
| ▸ | MMP12 | P39900 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MMP14 | P50281 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6937175 | 0.84 | HTR1A (0.52) | SLC6A4SLC6A2SLC6A3APOBEC3GMEN1 | |
| SCHEMBL4437976 | 0.83 | SLC6A2 (0.47) | SLC6A4SLC6A2SLC6A3KDM4EALDH1A1 | |
| SCHEMBL4808474 | 0.82 | MEN1 (0.66) | SLC6A4SLC6A2SLC6A3APOBEC3GMEN1 | |
| SCHEMBL7108674 | 0.81 | IDO1 (0.52) | SLC6A4SLC6A2SLC6A3APOBEC3GMEN1 | |
| SCHEMBL14089409 | 0.81 | SLC6A2 (0.56) | SLC6A4SLC6A2SLC6A3MEN1POLB | |
| SCHEMBL16956443 | 0.80 | ALDH1A1 (0.47) | SLC6A4SLC6A2SLC6A3MEN1KMT2A | |
| SCHEMBL10908428 | 0.79 | GAA (0.45) | SLC6A4SLC6A2SLC6A3APOBEC3GMEN1 | |
| SCHEMBL4448225 | 0.79 | SLC6A2 (0.43) | SLC6A4SLC6A2SLC6A3KDM4EALDH1A1 | |
| SCHEMBL4442278 | 0.78 | APOBEC3G (0.73) | SLC6A4SLC6A2SLC6A3APOBEC3GALDH1A1 | |
| SCHEMBL11881025 | 0.78 | SLC6A4 (0.49) | SLC6A4SLC6A2SLC6A3MEN1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2061754-A1 | BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008115999-A1 | BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2008-09-25 | — | — | WO | disclosed |
| US-20080234384-A1 | BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234384-A1 | BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS | FECH, SLC10A1, SLC40A1 | SLC6A4 724/4885SLC6A2 247/4885SLC6A3 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.